M2抗体重组人源靶抗原二联体在原发性胆汁性肝硬化患者中的检测及应用

目的 利用重组抗原BCOADA-E2和PDC-E2的二联体（BP），检测PBC患者血清中的M2抗体并探讨其临床意义。方法 经Ni—NTA亲和柱纯化重组表达的BP融合蛋白，分别建立免疫印迹法（IBT）和酶链免疫吸附（ELISA）法检测60份PBC患者血清，以60份其他肝病患者、60份自身免疫病患者、80例正常人血清为对照组。结果 经常规试剂盒检测为M2（＋）的60份患者血清，利用重组抗原检测阳性53例，阴性7例，阳性率为88．3％；经常规试剂盒检测为M2（-）的60份自身免疫病患者血清、60份其他肝病患者和80例正常人血清，利用重组抗原检测为M2（-）。结论 利用重组抗原BP检测M2抗体敏感性较高。对临床辅助诊断PBC提供一定的手段。

Detection of anti-M2 autoantibody using recombinant BP

Objective To detect anti-M2 autoantibody using recombinant BCOADA-E2-PDC-E2(BP).Methods We purified recombinant BP by Ni2+ affinity chromatography column and then established immune blotting test(IBT) and enzyme Linked Immunosorbent assays(ELISA) to detect anti-M2 autoantibody in the sera of patients with primary biliary cirrhosis(PBC),compared with groups of healthy,other liver diseases and other autoimmune diseases.Results Among 60 sera from PBC patients,53 were positive,while all controls were negative.The positive rate was 88.3%.Conclusion The recombinant BP could be used to detect anti-M2 autoantibody specially and sensitively,helpful for diagnosis of PBC.